Francis R S
Thorax. 1976 Jun;31(3):309-14. doi: 10.1136/thx.31.3.309.
Following a short-term clinical trial reported elsewhere, beclomethasone dipropionate aerosol has been given to 15 children with asthma for between 2 1/2 and 3 years except for a short placebo period after the first year. Month-by-month records of wheezing, peak flow rate, and other treatments used are presented for the first 17 months, adrenocortical function tests are reported for the first 2 years, and growth is recorded for 2 1/2-3 years. The short-term clinical benefits of the treatment are confirmed in the longer term, adrenocortical function appears to be unchanged, and growth proceeds along expected lines. The main disadvantage seems to be worsening of eczema and allergic rhinitis in those children who have ceased using corticotrophin or oral steroids for the control of asthma. It is concluded that in the long term beclomethasone dipropionate aerosol provides safe and effective day-to-day control of asthma in children, although occasional recourse to systemic steroid therapy cannot be avoided. Oral candidasis has not been a clinical problem.
在别处报道的一项短期临床试验之后，除第一年之后有一个短的安慰剂期外，已对15名哮喘儿童给予丙酸倍氯米松气雾剂治疗2年半至3年。给出了前17个月逐月的喘息、峰值流速及所使用的其他治疗记录，报告了前2年的肾上腺皮质功能测试结果，并记录了2年半至3年的生长情况。该治疗的短期临床益处得到了长期证实，肾上腺皮质功能似乎未改变，生长按预期进行。主要缺点似乎是在那些已停止使用促肾上腺皮质激素或口服类固醇来控制哮喘的儿童中湿疹和变应性鼻炎加重。得出的结论是，从长期来看，丙酸倍氯米松气雾剂可安全有效地日常控制儿童哮喘，尽管偶尔仍不可避免地需要全身用类固醇治疗。口腔念珠菌病尚未成为临床问题。
